Global pharma companies and Japan can create a win-win situation through a new pricing mechanism, writes Nobuko Kobayashi.
Nobuko Kobayashi
Advertisement
Nobuko Kobayashi is a partner in global management consulting firm A.T. Kearney’s Consumer Goods and Retail Practice, serving Japanese and multinational clients in consumer industries.
Articles by Nobuko Kobayashi
Innovations in Big Data will have a lasting impact on care and present an opportunity for U.S. pharmaceutical companies, writes Nobuko Kobayashi.
Advertisement
Latest Updated Articles
- Big Data & Japan's Aging Population: Opening the Door for US Pharma
Published: May 14th 2018 | Updated:
Japan: Balancing Cost and Innovation through PricingPublished: July 9th 2018 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly to Submit Oral GLP-1 for FDA Priority Review Program: Report
2
Pharmaceutical Executive Daily: Novo Nordisk's Unsolicited Acquisition Proposal
3
GCC Emerges as a New Strategic Anchor for Global Venture Capital
4
Pharmaceutical Executive Presents: Most Favored Nation Order - How Trump Is Disrupting Pharma
5
